Direct-acting antivirals (DAAs) can cure hepatitis C (HCV) in more than 95% of individuals treated. But only 1 in 3 people with HCV in the U.S. receive treatment within a year of diagnosis. A new study by investigators from Mass General Brigham and University of Virginia School of Medicine has analyzed a large national prescription database to estimate hepatitis C treatment courses over time and trends by patient and prescriber characteristics from 2013–2025.
This article was originally published on MedicalXpress.com
